BioStem Technologies (BSEM) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pluri (PLUR) has outperformed BioStem Technologies (BSEM) over the past year, losing 75.3% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -95.6% for PLUR. Pluri is the larger company by market cap ($13.5 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | PLUR |
|---|---|---|
| Share price | $0.6351 | $0.94 |
| Market cap | $12.18M | $13.51M |
| 1-day change | -10.23% | -3.07% |
| YTD return | -83.33% | -68.56% |
| 1-year return | -83.98% | -75.26% |
| 5-year return | -55.90% | -95.63% |
| P/E ratio (TTM) | 0.72 | — |
| Forward P/E | 2.19 | — |
| EPS (TTM) | $0.88 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.02M |
| Revenue growth (YoY) | — | -23.95% |
| Net income (latest FY) | — | $-23.82M |
| Gross margin | — | 44.59% |
| Operating margin | — | -2454.53% |
| Net margin | — | -2344.59% |
| 52-week high | $8.40 | $3.94 |
| 52-week low | $0.5347 | $0.85 |
| Distance from 52-week high | -92.44% | -76.14% |
| Analyst consensus | none | — |
| Avg. price target upside | +1002.19% | — |
| Average volume | 194.93K | 36.98K |
| Shares outstanding | 19.18M | 14.38M |
| Employees | 73 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
BSEM vs PLUR FAQ
Which is bigger, BioStem Technologies or Pluri?
Pluri (PLUR) is larger, with a market capitalization of $13.51M compared with $12.18M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or PLUR?
PLUR returned -75.26% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Pluri in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.